[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545245":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":15,"centralContacts":21,"locations":26,"responsibleParty":50,"collaborators":7,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":7,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":7,"enrollmentInfo":62,"targetDuration":7,"studyType":65,"phases":7,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Xijing Hospital","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"PROCEDURE","Transcatheter aortic valve replacement","A total of 1000 consecutive patients with aortic valve disease undergoing TAVR will be enrolled. Clinical follow-up will be conducted in the periprocedural and after TAVR at 1 month, 5 years, and 10 years",[14],"Transcatheter aortic valve implantation",[16,19],{"name":17,"affiliation":5,"role":18},"Ling Tao, M.D, Ph.D","STUDY_CHAIR",{"name":20,"affiliation":5,"role":18},"Rutao Wang, M.D, Ph.D",[22],{"name":20,"role":23,"phone":24,"phoneExt":7,"email":25},"CONTACT","+86-15091095796","rutaowang@qq.com",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Xi'an","Shannxi","710032","China","CN",{"type":35,"coordinates":36},"Point",[37,38],108.92861,34.25833,{"lat":38,"lon":37},[41,43,47],{"name":42,"role":23,"phone":24,"phoneExt":7,"email":25},"Rutao Wang, M.D., Ph.D.",{"name":44,"role":23,"phone":45,"phoneExt":7,"email":46},"Ruining Zhang, BSc","+86-15802990370","ruining-zhang@qq.com",{"name":48,"role":49,"phone":7,"phoneExt":7,"email":7},"Ling Tao, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"LingTao","Professor in Cardiology, Director of the department of Cardiology","100545245","long-term-prognosis-and-valve-durability-of-tavr-100545245",false,"NCT06379386","Long-term Prognosis and Valve Durability of TAVR","Long-term Prognosis and Valve Durability of Transcatheter Aortic Valve Replacement for Aortic Valve Disease: a Real-world, Prospective, Single-center, Observational Study","Inclusion Criteria:\n\nPatients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.\n\n2\\. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form\n\n* 1\\. Patients with aortic stenosis or aortic valve insufficiency who were evaluated by the Heart team and underwent TAVR therapy\n* 2\\. Patients who understand the purpose of the study, agree to participate in the trial and sign the informed consent form\n\nExclusion Criteria:\n\n* 1\\. Patients who cannot provide informed consent\n* 2\\. Patients who are participating in other clinical trials","ALL","18 Years",{"count":63,"type":64},1000,"ESTIMATED","OBSERVATIONAL","This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics, procedural data, and clinical outcomes will be collected in a prospective and observational manner.",[68],"Aortic Valve Stenosis and Insufficiency",[70,71,72,73],"Aortic Valve Disease","TAVR","Prognosis","Valve durability","2024-04-18",{"date":76,"type":77},"2024-04-23","ACTUAL",{"date":79,"type":77},"2016-01",{"date":81,"type":64},"2030-12",{"name":5,"class":6},1]